{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:10:01Z","timestamp":1792167001546,"version":"4.4.0"},"reference-count":107,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:00:00Z","timestamp":1457481600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>In the recent past, the gene therapy field has witnessed a remarkable series of successes, many of which have involved primary immunodeficiency diseases, such as X-linked severe combined immunodeficiency, adenosine deaminase deficiency, chronic granulomatous disease, and Wiskott-Aldrich syndrome. While such progress has widened the choice of therapeutic options in some specific cases of primary immunodeficiency, much remains to be done to extend the geographical availability of such an advanced approach and to increase the number of diseases that can be targeted. At the same time, emerging technologies are stimulating intensive investigations that may lead to the application of precise genetic editing as the next form of gene therapy for these and other human genetic diseases.<\/ns4:p>","DOI":"10.12688\/f1000research.7512.1","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T10:53:16Z","timestamp":1457520796000},"page":"310","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Advances of gene therapy for primary immunodeficiencies"],"prefix":"10.12688","volume":"5","author":[{"given":"Fabio","family":"Candotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2016,3,9]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"696-726","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015.","volume":"35","author":"C Picard","year":"2015","journal-title":"J Clin Immunol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"602-10.e1\u201311","DOI":"10.1016\/j.jaci.2010.06.015","article-title":"Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?","volume":"126","author":"A Gennery","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"ref-3","first-page":"1-24","article-title":"Retroviral vectors.","volume":"158","author":"A Miller","year":"1992","journal-title":"Curr Top Microbiol Immunol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"475-80","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.","volume":"270","author":"R Blaese","year":"1995","journal-title":"Science."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"470-5","DOI":"10.1126\/science.270.5235.470","article-title":"Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.","volume":"270","author":"C Bordignon","year":"1995","journal-title":"Science."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1017-23","DOI":"10.1038\/nm1095-1017","article-title":"Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.","volume":"1","author":"D Kohn","year":"1995","journal-title":"Nat Med."},{"key":"ref-7","first-page":"179-83","article-title":"Bone marrow gene transfer in three patients with adenosine deaminase deficiency.","volume":"3","author":"P Hoogerbrugge","year":"1996","journal-title":"Gene Ther."},{"key":"ref-8","doi-asserted-by":"crossref","first-page":"1878-86","DOI":"10.1182\/blood.V92.6.1878","article-title":"Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor.","volume":"92","author":"H Kiem","year":"1998","journal-title":"Blood."},{"key":"ref-9","doi-asserted-by":"crossref","first-page":"1131-41","DOI":"10.1182\/blood.V92.4.1131","article-title":"Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability.","volume":"92","author":"J Tisdale","year":"1998","journal-title":"Blood."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"669-72","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.","volume":"288","author":"M Cavazzana-Calvo","year":"2000","journal-title":"Science."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"2410-3","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.","volume":"296","author":"A Aiuti","year":"2002","journal-title":"Science."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"2181-7","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.","volume":"364","author":"H Gaspar","year":"2004","journal-title":"Lancet."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"1918-27","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome.","volume":"363","author":"K Boztug","year":"2010","journal-title":"N Engl J Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"3132-42","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"3143-50","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.","volume":"118","author":"S Howe","year":"2008","journal-title":"J Clin Invest."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.","volume":"6","author":"C Braun","year":"2014","journal-title":"Sci Transl Med."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"147-57","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans.","volume":"73","author":"M Noguchi","year":"1993","journal-title":"Cell."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"1099-104","DOI":"10.1093\/hmg\/2.8.1099","article-title":"The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1.","volume":"2","author":"J Puck","year":"1993","journal-title":"Hum Mol Genet."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"590-8","DOI":"10.1038\/sj.mt.6300393","article-title":"Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.","volume":"16","author":"S Thornhill","year":"2008","journal-title":"Mol Ther."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1407-17","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency.","volume":"371","author":"S Hacein-Bey-Abina","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1749-51","DOI":"10.1126\/science.1083413","article-title":"Transcription start regions in the human genome are favored targets for MLV integration.","volume":"300","author":"X Wu","year":"2003","journal-title":"Science."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"900-8","DOI":"10.1182\/blood-2009-10-250209","article-title":"A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.","volume":"116","author":"S Zhou","year":"2010","journal-title":"Blood."},{"key":"ref-23","doi-asserted-by":"crossref","first-page":"261-261","DOI":"10.1182\/blood.V126.23.261.261","article-title":"Lentiviral Hematopoietic Stem Cell Gene Therapy for Older Patients with X-Linked Severe Combined Immunodeficiency.","volume":"126","author":"S De Ravin","year":"2015","journal-title":"Blood."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"6288-95","DOI":"10.1182\/blood-2008-12-115253","article-title":"Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome.","volume":"113","author":"M Bosticardo","year":"2009","journal-title":"Blood."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"1675-84","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study.","volume":"118","author":"D Moratto","year":"2011","journal-title":"Blood."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"903-15","DOI":"10.1016\/j.ymthe.2004.08.008","article-title":"Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction.","volume":"10","author":"L Dupr\u00e9","year":"2004","journal-title":"Mol Ther."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.","volume":"341","author":"A Aiuti","year":"2013","journal-title":"Science."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1550-63","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.","volume":"313","author":"S Hacein-Bey Abina","year":"2015","journal-title":"JAMA."},{"key":"ref-29","first-page":"260-260","article-title":"Gene Therapy Using a Self-Inactivating Lentiviral Vector Improves Clinical and Laboratory Manifestations of Wiskott-Aldrich Syndrome.","volume":"126","author":"J Chu","year":"2015","journal-title":"Blood."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1319-26","DOI":"10.1016\/j.jaci.2011.03.028","article-title":"Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.","volume":"127","author":"E Kang","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"ref-31","first-page":"486a","article-title":"Prolonged detection of oxidase-positive neutrophils in the peripheral blood of five patients following a single cycle of gene therapy for chronic granulomatous disease.","volume":"88","author":"H Malech","year":"1996","journal-title":"Blood."},{"key":"ref-32","first-page":"690A","article-title":"Extended production of oxidase normal neutrophils in X-linked chronic granulomatous disease (CGD) following gene therapy with gp91(phox) transduced CD34+ cells.","volume":"92","author":"H Malech","year":"1998","journal-title":"Blood."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"86-92","DOI":"10.1159\/000072457","article-title":"Gene therapy for chronic granulomatous disease.","volume":"110","author":"W Goebel","year":"2003","journal-title":"Acta Haematol."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"783-91","DOI":"10.1182\/blood-2009-05-222760","article-title":"Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.","volume":"115","author":"E Kang","year":"2010","journal-title":"Blood."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"28-35","DOI":"10.1038\/mt.2010.232","article-title":"Gene therapy of chronic granulomatous disease: the engraftment dilemma.","volume":"19","author":"M Grez","year":"2011","journal-title":"Mol Ther."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"401-9","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.","volume":"12","author":"M Ott","year":"2006","journal-title":"Nat Med."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"198-204","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.","volume":"16","author":"S Stein","year":"2010","journal-title":"Nat Med."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"585-91","DOI":"10.1016\/j.coi.2012.07.012","article-title":"Gene therapy for primary immunodeficiencies: Part 2.","volume":"24","author":"A Aiuti","year":"2012","journal-title":"Curr Opin Immunol."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"2619-22","DOI":"10.1182\/blood-2009-05-221606","article-title":"Restoration of NET formation by gene therapy in CGD controls aspergillosis.","volume":"114","author":"M Bianchi","year":"2009","journal-title":"Blood."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"416-27","DOI":"10.2174\/1566523215666150515145255","article-title":"Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing.","volume":"15","author":"U Siler","year":"2015","journal-title":"Curr Gene Ther."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"111-8","DOI":"10.1038\/gt.2008.143","article-title":"Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells.","volume":"16","author":"B Moreno-Carranza","year":"2009","journal-title":"Gene Ther."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"122-32","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.","volume":"19","author":"G Santilli","year":"2011","journal-title":"Mol Ther."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"436-48","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.","volume":"383","author":"T G\u00fcng\u00f6r","year":"2014","journal-title":"Lancet."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"1472-83","DOI":"10.1038\/mt.2014.87","article-title":"Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.","volume":"22","author":"M Chiriaco","year":"2014","journal-title":"Mol Ther."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"188-230","DOI":"10.1093\/med\/9780195389838.003.0014","article-title":"Immunodeficiency Due to Defects of Purine Metabolism: Territorial Administration under Attack in Orleans and Washington","author":"R Hirschhorn","year":"2013"},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"3524-32","DOI":"10.1182\/blood-2009-06-189209","article-title":"How I treat ADA deficiency.","volume":"114","author":"H Gaspar","year":"2009","journal-title":"Blood."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"3615-24; quiz 3626","DOI":"10.1182\/blood-2011-12-396879","article-title":"Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.","volume":"120","author":"A Hassan","year":"2012","journal-title":"Blood."},{"key":"ref-48","doi-asserted-by":"crossref","first-page":"30-6","DOI":"10.1182\/blood.V91.1.30","article-title":"Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.","volume":"91","author":"M Onodera","year":"1998","journal-title":"Blood."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"24-7","DOI":"10.1006\/mthe.2000.0232","article-title":"Gene-transferred oligoclonal T cells predominantly persist in peripheral blood from an adenosine deaminase-deficient patient during gene therapy.","volume":"3","author":"Y Misaki","year":"2001","journal-title":"Mol Ther."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"423-5","DOI":"10.1038\/nm0502-423","article-title":"Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.","volume":"8","author":"A Aiuti","year":"2002","journal-title":"Nat Med."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"2563-9","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.","volume":"101","author":"L Muul","year":"2003","journal-title":"Blood."},{"key":"ref-52","first-page":"1437-1437","article-title":"Update on a Japanese clinical trial of stem cell gene therapy for ADA-deficiency.","volume":"21","author":"M Otsu","year":"2010","journal-title":"Human Gene Therapy."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"447-58","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency.","volume":"360","author":"A Aiuti","year":"2009","journal-title":"N Engl J Med."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"505-13","DOI":"10.1016\/j.ymthe.2006.06.007","article-title":"Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.","volume":"14","author":"H Gaspar","year":"2006","journal-title":"Mol Ther."},{"key":"ref-55","doi-asserted-by":"crossref","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.","volume":"3","author":"H Gaspar","year":"2011","journal-title":"Sci Transl Med."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"3635-46","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.","volume":"120","author":"F Candotti","year":"2012","journal-title":"Blood."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"607-22","DOI":"10.1038\/mt.2013.265","article-title":"Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.","volume":"22","author":"D Carbonaro","year":"2014","journal-title":"Mol Ther."},{"key":"ref-58","first-page":"S167-S168","article-title":"Immunological and Metabolic Correction After Lentiviral Vector Mediated Haematopoietic Stem Cell Gene Therapy for ADA Deficiency.","volume":"34","author":"B Gaspar","year":"2014","journal-title":"Journal of Clinical Immunology."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"1471-83","DOI":"10.1038\/leu.2011.106","article-title":"Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer.","volume":"25","author":"K Pike-Overzet","year":"2011","journal-title":"Leukemia."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"1968-80","DOI":"10.1038\/mt.2012.110","article-title":"Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.","volume":"20","author":"N van Til","year":"2012","journal-title":"Mol Ther."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"1116-23","DOI":"10.1016\/j.jaci.2013.10.009","article-title":"Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.","volume":"133","author":"N van Til","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"242-3","DOI":"10.1016\/j.jaci.2014.04.033","article-title":"Successful RAG1-SCID gene therapy depends on the level of RAG1 expression.","volume":"134","author":"K Pike-Overzet","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"16406-11","DOI":"10.1073\/pnas.0608130103","article-title":"Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer.","volume":"103","author":"G Mostoslavsky","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"1490-9","DOI":"10.1038\/mt.2008.118","article-title":"Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells.","volume":"16","author":"F Benjelloun","year":"2008","journal-title":"Mol Ther."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"396-403","DOI":"10.1038\/sj.mt.6300353","article-title":"Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34+ cells isolated from Artemis or RAG1-deficient patients.","volume":"16","author":"C Lagresle-Peyrou","year":"2008","journal-title":"Mol Ther."},{"key":"ref-66","doi-asserted-by":"crossref","first-page":"3006-14","DOI":"10.4049\/jimmunol.154.6.3006","article-title":"Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression.","volume":"154","author":"D Nelson","year":"1995","journal-title":"J Immunol."},{"key":"ref-67","first-page":"383-8","article-title":"Gene therapy for leukocyte adhesion deficiency.","volume":"2","author":"T Bauer","year":"2000","journal-title":"Curr Opin Mol Ther."},{"key":"ref-68","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1016\/S1525-0016(16)41606-0","article-title":"A clinical attempt to treat JAK3-deficient SCID using retroviral-mediated gene transfer to bone marrow CD34+ cells.","volume":"7","author":"B Sorrentino","year":"2003","journal-title":"Molecular Therapy."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"646-51","DOI":"10.1038\/nature03556","article-title":"Highly efficient endogenous human gene correction using designed zinc-finger nucleases.","volume":"435","author":"F Urnov","year":"2005","journal-title":"Nature."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"235-40","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating haematopoietic stem cells.","volume":"510","author":"P Genovese","year":"2014","journal-title":"Nature."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"5561-72","DOI":"10.1182\/blood-2010-12-328161","article-title":"Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting.","volume":"117","author":"J Zou","year":"2011","journal-title":"Blood."},{"key":"ref-72","doi-asserted-by":"crossref","first-page":"7842-9","DOI":"10.1016\/S0021-9258(17)42870-5","article-title":"Partial phenotypic correction of human Lesch-Nyhan (hypoxanthine-guanine phosphoribosyltransferase-deficient) lymphoblasts with a transmissible retroviral vector.","volume":"259","author":"R Willis","year":"1984","journal-title":"J Biol Chem."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"6563-7","DOI":"10.1073\/pnas.83.17.6563","article-title":"Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer.","volume":"83","author":"P Kantoff","year":"1986","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"1041-8","DOI":"10.1089\/hum.1997.8.9-1041","article-title":"Construction of retroviral vectors carrying human CD3 gamma cDNA and reconstitution of CD3 gamma expression and T cell receptor surface expression and function in a CD3 gamma-deficient mutant T cell line.","volume":"8","author":"J Sun","year":"1997","journal-title":"Hum Gene Ther."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"2687-92","DOI":"10.1084\/jem.183.6.2687","article-title":"In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction.","volume":"183","author":"F Candotti","year":"1996","journal-title":"J Exp Med."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"605-15","DOI":"10.1016\/S1074-7613(00)80274-5","article-title":"Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways.","volume":"5","author":"S Oakes","year":"1996","journal-title":"Immunity."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"58-64","DOI":"10.1038\/nm0198-058","article-title":"Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer.","volume":"4","author":"K Bunting","year":"1998","journal-title":"Nat Med."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"232-7","DOI":"10.1073\/pnas.96.1.232","article-title":"Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency.","volume":"96","author":"K Bunting","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"2353-64","DOI":"10.1089\/104303400750038462","article-title":"Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation.","volume":"11","author":"K Bunting","year":"2000","journal-title":"Hum Gene Ther."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"63-72","DOI":"10.1182\/blood-2005-05-2032","article-title":"Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity.","volume":"107","author":"C Lagresle-Peyrou","year":"2006","journal-title":"Blood."},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"3942-9","DOI":"10.1182\/blood-2002-03-0782","article-title":"Gene therapy of RAG-2-\/- mice: sustained correction of the immunodeficiency.","volume":"100","author":"F Yates","year":"2002","journal-title":"Blood."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"106-11","DOI":"10.1038\/ng.278","article-title":"Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness.","volume":"41","author":"C Lagresle-Peyrou","year":"2009","journal-title":"Nat Genet."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"1282-93","DOI":"10.1002\/jgm.1261","article-title":"Lentivirus gene therapy for purine nucleoside phosphorylase deficiency.","volume":"10","author":"P Liao","year":"2008","journal-title":"J Gene Med."},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"2031-6","DOI":"10.1084\/jem.184.5.2031","article-title":"Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene.","volume":"184","author":"N Taylor","year":"1996","journal-title":"J Exp Med."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"1392-400","DOI":"10.1038\/sj.gt.3301249","article-title":"Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy.","volume":"7","author":"M Steinberg","year":"2000","journal-title":"Gene Ther."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"1248-56","DOI":"10.1182\/blood-2002-01-0247","article-title":"Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells.","volume":"100","author":"M Otsu","year":"2002","journal-title":"Blood."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"2287-95","DOI":"10.1172\/JCI23966","article-title":"In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.","volume":"115","author":"O Adjali","year":"2005","journal-title":"J Clin Invest."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"e2059","DOI":"10.1371\/journal.pone.0002059","article-title":"ZAP-70 restoration in mice by in vivo thymic electroporation.","volume":"3","author":"M Irla","year":"2008","journal-title":"PLoS One."},{"key":"ref-89","doi-asserted-by":"crossref","first-page":"1086-95","DOI":"10.4049\/jimmunol.159.3.1086","article-title":"Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.","volume":"159","author":"M Bradley","year":"1997","journal-title":"J Immunol."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"1281-90","DOI":"10.1182\/blood-2003-09-3044","article-title":"Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer.","volume":"104","author":"P Yu","year":"2004","journal-title":"Blood."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"942-52","DOI":"10.1038\/gt.2008.17","article-title":"Development of an enhanced B-specific lentiviral vector expressing BTK: a tool for gene therapy of XLA.","volume":"15","author":"T Moreau","year":"2008","journal-title":"Gene Ther."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"2146-55","DOI":"10.1182\/blood-2009-09-241869","article-title":"B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.","volume":"115","author":"H Kerns","year":"2010","journal-title":"Blood."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"1617-30","DOI":"10.1038\/leu.2010.140","article-title":"Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK.","volume":"24","author":"Y Ng","year":"2010","journal-title":"Leukemia."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"1253-60","DOI":"10.1038\/3233","article-title":"Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice.","volume":"4","author":"M Brown","year":"1998","journal-title":"Nat Med."},{"key":"ref-95","doi-asserted-by":"publisher","first-page":"835-41","DOI":"10.1038\/nm1086","article-title":"Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency.","volume":"10","author":"M Tahara","year":"2004","journal-title":"Nat Med."},{"key":"ref-96","doi-asserted-by":"publisher","first-page":"364-71","DOI":"10.1038\/gt.2010.144","article-title":"A tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences.","volume":"18","author":"Z Romero","year":"2011","journal-title":"Gene Ther."},{"key":"ref-97","doi-asserted-by":"publisher","first-page":"737-45","DOI":"10.1038\/mt.2014.242","article-title":"Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency.","volume":"23","author":"M Carmo","year":"2015","journal-title":"Mol Ther."},{"key":"ref-98","doi-asserted-by":"publisher","first-page":"1073-6","DOI":"10.1182\/blood-2012-07-445858","article-title":"SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease.","volume":"121","author":"C Rivat","year":"2013","journal-title":"Blood."},{"key":"ref-99","doi-asserted-by":"publisher","first-page":"1413-6","DOI":"10.1126\/science.1972597","article-title":"Correction of CD18-deficient lymphocytes by retrovirus-mediated gene transfer.","volume":"248","author":"J Wilson","year":"1990","journal-title":"Science."},{"key":"ref-100","doi-asserted-by":"crossref","first-page":"2379-87","DOI":"10.1182\/blood.V86.6.2379.bloodjournal8662379","article-title":"Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a gibbon ape leukemia virus envelope.","volume":"86","author":"T Bauer","year":"1995","journal-title":"Blood."},{"key":"ref-101","doi-asserted-by":"crossref","first-page":"1520-6","DOI":"10.1182\/blood.V91.5.1520","article-title":"Retroviral-mediated gene transfer of the leukocyte integrin CD18 into peripheral blood CD34+ cells derived from a patient with leukocyte adhesion deficiency type 1.","volume":"91","author":"T Bauer","year":"1998","journal-title":"Blood."},{"key":"ref-102","doi-asserted-by":"publisher","first-page":"1443-8","DOI":"10.1093\/hmg\/2.9.1443","article-title":"Retroviral mediated expression of CD18 in normal and deficient human bone marrow progenitor cells.","volume":"2","author":"T Yorifuji","year":"1993","journal-title":"Hum Mol Genet."},{"key":"ref-103","doi-asserted-by":"publisher","first-page":"3313-20","DOI":"10.1182\/blood-2006-03-006908","article-title":"Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy.","volume":"108","author":"T Bauer","year":"2006","journal-title":"Blood."},{"key":"ref-104","doi-asserted-by":"publisher","first-page":"93-7","DOI":"10.1038\/nm1695","article-title":"Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.","volume":"14","author":"T Bauer","year":"2008","journal-title":"Nat Med."},{"key":"ref-105","doi-asserted-by":"publisher","first-page":"672-7","DOI":"10.1038\/gt.2010.7","article-title":"Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency.","volume":"17","author":"E Nelson","year":"2010","journal-title":"Gene Ther."},{"key":"ref-106","doi-asserted-by":"publisher","first-page":"113-21","DOI":"10.1038\/mt.2010.203","article-title":"Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression.","volume":"19","author":"M Hunter","year":"2011","journal-title":"Mol Ther."},{"key":"ref-107","doi-asserted-by":"publisher","first-page":"689-96","DOI":"10.1089\/hum.2010.130","article-title":"Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.","volume":"22","author":"M Hunter","year":"2011","journal-title":"Hum Gene Ther."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-310\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-310\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-310\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T18:21:20Z","timestamp":1718389280000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-310\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,9]]},"references-count":107,"URL":"https:\/\/doi.org\/10.12688\/f1000research.7512.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.8091.r12836","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.8091.r12837","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.8091.r12837","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.8091.r12836","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,9]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-310\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.8091.r12836, Ramsay Fuleihan, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 09 Mar 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-310\/v1#referee-response-12836","order":0,"name":"referee-response-12836","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.8091.r12837, Anete Grumach, Outpatient Group of Recurrent Infections, Faculty of Medicine ABC, Santo Andre, Brazil, 09 Mar 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-310\/v1#referee-response-12837","order":1,"name":"referee-response-12837","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by funding jointly granted by the University of Lausanne (UNIL) and the University Hospital of Lausanne (CHUV), Switzerland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}